Overview of Electroporation
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This special issue of Technology in Cancer Research and Treatment focuses on the versatility of electroporation. Contributed papers report on the basic mechanisms as well as the use of this procedure ex vivo and in vivo. In addition, recent studies utilizing in vivo electroporation for plasmid DNA and drug delivery are presented.
While the first report using electroporation to transfer DNA to mammalian cells was in 1982 (1), research performed in the 1960s and 1970s made important contributions to this important first demonstration (2-6). During the past 10 years, the applicability of electroporation has expanded from being strictly a laboratory method to being utilized in a variety of therapeutic applications. Both in vivo and ex vivo uses of this physical delivery method have greatly increased in recent years. Due to the physical nature of electroporation, it is applicable to most cell types and its utility in vivo is only dependent on accessibility of the tissue.
The first use of in vivo electroporation occurred in the late 1980s and was designed to enhance the uptake of a chemotherapeutic agent to tumor cells (7). This combination of chemotherapy and electroporation has been termed electrochemotherapy (ECT). This approach was successful and by the early 1990s the first clinical trial using in vivo electroporation to deliver bleomycin to squamous cell carcinomas of the head and neck was performed (8) . The successes of these early pre-clinical and clinical studies led to studies in several other tumor types. Pre-clinical studies have been performed by several groups around the world utilizing mice, rats, hamsters and rabbits with a variety of tumor types including, melanoma, hepatocellular carcinoma, lung carcinoma, breast adenocarcinoma, fibrosarcoma and glioma (9). In addition, several clinical studies have been performed (10). Both the human and animal studies have reported response rates of 70-99% and reported no significant adverse reactions to the therapy.
Electroporation has also been a useful tool for delivering plasmid DNA and has been widely used as an in vitro laboratory method. This, combined with the in vivo studies that showed electroporation can safely and efficiently deliver small molecules, were important building blocks to the use of electroporation to deliver plasmid DNA in vivo. Titomirov, et al., were the first to use in vivo electroporation to deliver plasmid DNA to the skin of newborn mice reported (11). Delivery of plasmid DNA to rat liver (12) and to rat brain tumors (13) using in vivo electroporation was reported in 1996. In the past 5 years, several reports have been published demonstrating this approach can be applied to other tissues such as skeletal muscle as well as tumor tissue such as melanoma and heptocellular carcinoma. Recent studies using in vivo electroporation to deliver plasmids coding for cytokine genes have been successful in treating established tumors and preventing the formation of new tumors in both in melanoma and squamous cell carcinoma models (14, 15) . The use of this delivery approach for gene transfer protocols has steadily increased. Publications reporting the use of this technique have gone from only two in 1996 to over 50 in 2001.
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